Front Page VSPN Message Boards Chat Library Continual Education Search MyVSPN - Coming Soon Help Frequently Asked Questions Send us Feedback! Go to VIN Industry Partners Go to VetQuest Go to Veterinary Partner Go to Y2Spay
 
Menu bar   Go to the VIN.com Portal
 

ABSTRACT OF THE WEEK

Today's Veterinary Practice
Volume 11 | Issue 5 (Sep-Oct 2021)

Multimodal Pain Management for Canine Osteoarthritis

Today's Vet Pract. Sep-Oct 2021;11(5):42-51. 47 Refs
Darryl Millis1
1 The University of Tennessee College of Veterinary Medicine, Knoxville, TN 37996, USA.

Author Abstract

Veterinarians should understand the process for developing a multimodal osteoarthritis treatment plan that aims to delay disease progression, decrease inflammation, and ultimately improve the patient’s quality of life.

Article Tools:
   Email to me

Archives Highlights:
Non-blinded treatment of aural -hematoma with oral prednisolone as a monotherapy in privately-owned dogs.
Clinicians treated 24 privately-owned dogs suffering from aural hematoma with oral prednisolone at 1?mg/kg/day for 14 days, followed by 0.5?mg/kg/day for another 14 days. The success was assessed subjectively after 14 days by the owner and after 28 days by a clinician or specialist. In 21 of 24 dogs, oral prednisolone treatment for 28 days led to a subjective clinical improvement of at least 80%.
Daytime and nocturnal activity in treated dogs with idiopathic epilepsy compared to matched unaffected controls.
Dogs with idiopathic epilepsy (IE) treated with antiepileptic drugs (AEDs) had an 18% average lower baseline activity level compared to control dogs. The combination of phenobarbital and potassium bromide (KBr) was associated with an average 28% decrease in activity in dogs with IE compared to control dogs. Mean sleep scores were not significantly different in dogs with IE receiving AEDs compared to control dogs. However, higher dosages of KBr were associated with lower sleep scores.
Clinical Efficacy and Safety of Malarone®, Azithromycin and Artesunate Combination for Treatment of Babesia gibsoni in Naturally Infected Dogs.
The dogs received combined therapy with Malarone (13.5 mg/kg PO q24 h), azithromycin (10 mg/kg PO q24 h), and artesunate (12.5 mg/kg PO q24 h) for 10 days. The combined treatment improved hematology and biochemical parameters to the reference range gradually during the first 14 days, resulting in stable values until day 56 after treatment. No clinically apparent adverse effects were reported during treatment and monitoring. No relapses of parasitemia were detected in control days 180, 360, 540, and 720 in all dogs.
A longitudinal study of the persistence of increased creatinine and concordance between kidney biomarkers in cats and dogs.
The study included 4517 cats and 4576 dogs with increased T1 creatinine concentrations and 54,295 cats and 125,403 dogs with T1 creatinine at or below the URL. The probability of a persistently increased creatinine at T2 was approximately 58% for cats and 49% for dogs after a T1 increase. For animals without a T1 increase the probability of increased creatinine at T2 was only 7% for cats and 3% for dogs. For cats and dogs with persistently increased Cr, the probability of an increased SDMA concentration at T1 was 70-75%. By 24 months, that probability rose to 94% for cats and 88% for dogs.
Canine coat pigmentation genetics: a review.
Some genes involved in canine pigmentation have been linked to aural, visual, and neurological impairments. In this paper, we discuss coat colour phenotypes in the domestic dog, the genes and variants responsible for these phenotypes, and any proven coat colour-associated health effects.

Back Print Save Bookmark in my Browser Email this article to me. Top of Page. VSPN AOW : Multimodal Pain Managemen...
Contact Us